Apellis Pharmaceuticals
Presença
Apellis Pharmaceuticals é uma das ...
Apellis Pharmaceuticals é uma empresa listada sob o símbolo APLS (US).
Executivos
Veja o organograma con seus 24 executivos principais
Biografias mais buscadas da Apellis Pharmaceuticals
- Cedric Francois, Chief Executive Officer and Director
- Gerald Chan, Chairman of the Board
- Alec Machiels, Director
Recentes movimentos de executivos em Apellis Pharmaceuticals
- Adam Townsend antes Chief Commercial Officer, foi promovido a Chief Operating Officer (Notícia publicada em 23 de janeiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da Apellis Pharmaceuticals.
Biotecnologia
Apellis Pharmaceuticals possui 2.282 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Apellis Pharmaceuticals
- Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
- Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity | Apellis Pharmaceuticals, Inc.
- Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week | Apellis Pharmaceuticals, Inc.
- Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need | Apellis Pharmaceuticals, Inc.
- Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit | Apellis Pharmaceuticals, Inc.
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020 | Apellis Pharmaceuticals, Inc.
- Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results | Apellis Pharmaceuticals, Inc.
- View more press releases Close
Redes sociais sobre Apellis Pharmaceuticals
- Apellis Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Apellis Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Cedric Francois 
Ligue para a Apellis Pharmaceuticals em +1 502...
